BiotechTube

EMB-01 + Osimertinib

Phase 1/2UNKNOWN
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Lung Non-Small Cell Carcinoma

Conditions

Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors

Trial Timeline

Jun 1, 2023 → Dec 1, 2024

NCT ID
NCT05498389

About EMB-01 + Osimertinib

EMB-01 + Osimertinib is a phase 1/2 stage product being developed by LabCorp for Metastatic Lung Non-Small Cell Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05498389. Target conditions include Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05498389Phase 1/2UNKNOWN

Competing Products

20 competing products in Metastatic Lung Non-Small Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from LabCorp

VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + PlaceboPhase 2
49
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + PlaceboPhase 2
49
EMB-01Phase 1/2
38
InfigratinibPhase 1/2
38
NM8074 + PlaceboPhase 1
30